If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Atrovent Now Available for Children Six Years And Up RIDGEFIELD, CT -- Oct. 5, 1998 -- Boehringer Ingelheim Pharmaceuticals, Inc.’s Atrovent(R) (ipratropium bromide) Nasal Spray .03 percent is now available for use in children six years and up to treat a runny nose associated with allergic and nonallergic perennial rhinitis. It is not for the relief of nasal congestion, sneezing, or postnasal drip. A runny nose (rhinorrhea) can be caused by allergic reactions to dust, pollen, mould spores or animal dander, as well as by other irritants, such as fumes, odours, smoke and atmospheric or temperature changes. A runny nose, an annoying symptom of rhinitis, occurs when an allergen or irritant triggers the release of acetylcholine, a chemical that stimulates the glands in the nose to produce nasal secretions. Atrovent blocks the action of acetylcholine, which causes a runny nose. The drug is not addictive and does not cause nasal rebound, a worsening of symptoms after you stop using it. "Avoiding exposure to allergens is the first, but often most difficult, step to preventing a runny nose," said Diane Schuller, M.D., professor of pediatrics, with the Milton S. Hershey Medical College at Pennsylvania State University, and chief of the division of allergy, immunology and pulmonology, with the Milton S. Hershey Medical Center at the Pennsylvania State University. "Once children have been exposed and experience a continuously runny nose, medications such as Atrovent Nasal Spray .03 percent can bring significant relief." Clinical studies in adults with Atrovent demonstrate that it provides safe and effective relief from a runny nose. The most frequently reported nasal adverse effects were transient episodes of nasal bleeding (9.0 percent versus 4.6 percent with vehicle) or nasal dryness (5.1 percent versus 0.9 percent with vehicle). The most frequently reported non-nasal adverse events were transient episodes of headache (9.8 percent versus 9.2 percent with saline nasal spray) or upper respiratory tract infections (9.8 percent versus 7.2 percent with saline nasal spray). Atrovent was first introduced in February 1996 for use in adults and adolescents 12 years and older for treating a runny nose associated with allergic and nonallergic perennial rhinitis. Related Links: Atrovent, Boehringer Ingelheim Pharmaceuticals, Inc.
|
